| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Stanley C Jordan | |
| Mark D Pescovitz | |||
| P433 | issue | 3 | |
| P304 | page(s) | 421-432 | |
| P577 | publication date | 2006-04-12 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Presensitization: the problem and its management | |
| P478 | volume | 1 |
| Q43495245 | A sterile elastic exsanguination tourniquet is effective in preventing blood loss during hemodialysis access surgery. |
| Q44075598 | Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q42951982 | An Integrative Approach for the Transplantation of High-Risk Sensitized Patients |
| Q46921326 | Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab |
| Q89474375 | Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q92112007 | Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients |
| Q48527007 | Association between the polymorphism of HLA and ESRD in Dalian Han population located in north of China |
| Q58700304 | Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells |
| Q39101892 | B Cell Immunity in Solid Organ Transplantation. |
| Q42016816 | B-cell-dependent memory T cells impede nonmyeloablative mixed chimerism induction in presensitized mice |
| Q34159016 | B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. |
| Q38002449 | Cardiac antibody-mediated rejection |
| Q37626123 | Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. |
| Q26780271 | Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation |
| Q79815538 | Cross Reactive Epitope Group antibodies in sensitized kidneys transplant recipients was associated with early acute Antibody Mediated Rejection |
| Q37836967 | Current approaches to the management of highly sensitized kidney transplant patients |
| Q42872373 | Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies |
| Q38001495 | Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe? |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q52888455 | Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. |
| Q49644436 | Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies |
| Q34204510 | Haemodialysing babies weighing <8 kg with the Newcastle infant dialysis and ultrafiltration system (Nidus): comparison with peritoneal and conventional haemodialysis |
| Q36843406 | High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients |
| Q36028067 | Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. |
| Q36901669 | Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients |
| Q38048511 | Intestinal and multivisceral transplantation immunosuppression protocols--literature review |
| Q51579669 | Kidney transplantation for high-risk sensitized patients - the "Heidelberg algorithm". |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q51413561 | Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. |
| Q27010224 | Modern approaches to incompatible kidney transplantation |
| Q40405351 | Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system |
| Q44205594 | Panel-reactive antibody levels and renal transplantation rates in sensitized patients after desensitization and human leucocyte antigen amino acid residue matching |
| Q41510934 | Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys |
| Q47136558 | Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate? |
| Q37373575 | Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates |
| Q37171317 | Positive B-cell only flow cytometric crossmatch: implications for renal transplantation |
| Q33998148 | Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. |
| Q45784756 | Probability of deceased donor kidney transplantation based on % PRA. |
| Q91699028 | Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice |
| Q37877263 | Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation |
| Q39289605 | Renal transplantation in sensitized children and young adults: a nationwide approach |
| Q93142076 | Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant |
| Q46311126 | Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. |
| Q89777486 | Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates |
| Q45195699 | Successful third kidney transplantation with intensive immunosuppression in a highly sensitized recipient |
| Q50111204 | The role of initial hemodialysis vascular access in the outcome of subsequent kidney transplantation |
| Q36102133 | Tolerogenic therapies in transplantation. |
| Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
| Q82564717 | [Transplantation strategies in immunized and hyperimmunized patients] |
Search more.